NCT04817007 2026-05-08A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)Bristol-Myers SquibbPhase 1/2 Active not recruiting216 enrolled